Trade FibroGen, Inc - FGEN CFD

Add to favourite

0.30

6.25%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.05

Long position overnight fee

-0.023485%

Short position overnight fee

0.001262%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

50.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	0.32
Open	0.32
1-Year Change	-84.54%
Day's Range	0.3 - 0.32

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Mar 28, 2025	0.30	-0.02	-6.25%	0.32	0.32	0.30
Mar 27, 2025	0.32	0.00	0.00%	0.32	0.32	0.32
Mar 26, 2025	0.33	0.00	0.00%	0.33	0.33	0.32
Mar 25, 2025	0.34	0.00	0.00%	0.34	0.34	0.34
Mar 24, 2025	0.34	0.04	13.33%	0.30	0.34	0.30
Mar 21, 2025	0.30	-0.02	-6.25%	0.32	0.32	0.30
Mar 20, 2025	0.33	0.00	0.00%	0.33	0.33	0.33
Mar 19, 2025	0.33	0.00	0.00%	0.33	0.33	0.33
Mar 18, 2025	0.32	-0.01	-3.03%	0.33	0.35	0.29
Mar 17, 2025	0.42	0.00	0.00%	0.42	0.42	0.39
Mar 14, 2025	0.41	0.00	0.00%	0.41	0.43	0.41
Mar 13, 2025	0.40	-0.05	-11.11%	0.45	0.45	0.39
Mar 12, 2025	0.44	0.05	12.82%	0.39	0.46	0.39
Mar 11, 2025	0.39	0.03	8.33%	0.36	0.40	0.36
Mar 10, 2025	0.37	-0.01	-2.63%	0.38	0.38	0.37
Mar 7, 2025	0.37	0.00	0.00%	0.37	0.37	0.37
Mar 6, 2025	0.37	0.02	5.71%	0.35	0.38	0.35
Mar 5, 2025	0.35	0.01	2.94%	0.34	0.36	0.34
Mar 4, 2025	0.35	0.01	2.94%	0.34	0.35	0.33
Mar 3, 2025	0.36	-0.03	-7.69%	0.39	0.39	0.36

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

2:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

FibroGen, Inc Company profile

About FibroGen Inc

FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, FibroGen Inc revenues increased 33% to $235.3M. Net loss increased 53% to $290M. Revenues reflect Europe segment increase of 95% to $131.2M. Higher net loss reflects Research and Development -Balancing increase of 68% to $346.5M (expense), General and Administrative -Balancing increase of 27% to $89.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.11 to -$3.14.

Industry:

Biotechnology & Medical Research (NEC)

409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US